Description
Obinutuzumab, marketed under the brand name GAZYVA, It is an prescription medication that has been approved obinutuzumab (Gazyva) on different dates for different uses:
February 26, 2016
Approved for treating patients with follicular lymphoma (FL) who have relapsed, progressed, or are refractory to a rituximab-containing regimen
November 1, 2013
Approved for treating patients with chronic lymphocytic leukemia (CLL) in combination with chlorambucil
November 16, 2017
Approved for treating adults with untreated, stage II bulky, stage III, or stage IV FL in combination with chemotherapy
What is Gazyva (Obinutuzumab) ?
Gazyva is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with:
B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Source Content From US FDA
How to order approved “Gazyva (Obinutuzumab) for injection” Medicine?
GAZYVA (Obinutuzumab) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing GAZYVA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.